Researchers show that components similar to 'aspirin' could prevent type 2 diabetes in obese.
A study led by José Manuel Fernández Real, from the Biomedical Research Institute of Girona and the Biomedical Research Center on Network on Pathophysiology of Obesity and Nutrition (CIBEROBN), shows that the components similar to 'aspirin' could prevent diabetes type diabetes2 In people with obesity.The work is published in the magazine 'Journal of Clinical Endocrinology & AMP;Metabolism '.
The results showed that the components similar to 'aspirin', called salicylates, increased the amount of insulin produced by healthy obese people.Obesity is associated with insulin resistance, the first step towards type 2 diabetes.
The 'aspirin' and other salicylates are known for reducing blood glucose in diabetic patients.Research reveals a similar beneficial effect among obese individuals by increasing the amount of insulin secreted to blood circulation.
According to José Manuel Fernández Real, "the Salicilate administration led to a reduction in serum glucose concentrations. These discoveries underline the importance of carrying out more research on the possible therapeutic benefit of the 'aspirin' in the fight against type diabetes type2 ".
In their study, the Spaniards evaluated the effects of triflusal, a salicylate derivative, about 29 women and 9 men.The average age of the participants was 48 years and their body mass index (BMI) of 33.9.An BMI greater than 30 is considered obesity.For three and four weeks of treatment, these people received a dose of 600 milligrams (mg), 900 mg or placebo once a day.
The researchers discovered that the Triflusal administration led to a decrease in rapid serum combustion glucose.Contrary to their expectations, insulin sensitivity did not change significantly during the study.Insulin secretion, however, increased significantly in relation to dose size.
Together with humans, researchers also conducted laboratory studies on insulin producing cells, known as Langerhans islet, mice and humans.The authors observed that the triflusal significantly increased the insulin secreted by these cells.
"It has been recognized that aspirin therapy improves glucose tolerance and reduces insulin requirements in diabetic subjects. As far as we know, this is the first study that shows that salicylates lowered serum glucose in non -diabetic obese subjects.We believe that this effects was due to an untened previous increase in insulin secretion instead of an improvement in insulin sensitivity, "explains Fernández Real.
